Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Contingency plans required on chemo supply – Irish Cancer Society

By Mindo - 02nd Oct 2018 | 17 views

Aside from well-publicised supply problems in May 2017, the HSE has confirmed to the <strong><em>Medical Independent</em></strong> (<strong><em>MI</em></strong>) that “there was some other capacity issues experienced, but to a much lesser degree including some difficulties around Storm Ophelia and Storm Emma. These issues were also managed similarly.”

Baxter Healthcare Ltd is currently the only Irish-based provider of compounded systemic anti-cancer therapy (SACT). There are also a number of licensed UK-based suppliers who supply hospitals in Ireland.

In May 2017 Baxter Healthcare experienced a capacity issue. “A total of 10 hospitals were affected and 65 patients had their treatment delayed by one week or less, of these three were moved to another hospital for treatment and four had their treatment modified in some way,” according to a HSE spokesperson.

The Irish Cancer Society informed <strong><em>MI</em></strong> that with a reduction in the commercial supply of chemotherapy products, reduced competition for suppliers from outside markets to supplement hospital compounding facilities and the trade challenges a hard Brexit may pose to supply, “stringent policies and contingency plans” need to be put in place to ensure continuity and security of chemotherapy supply. “This is badly needed to avoid disruption and delays to treatment and the safe administration of treatment.”

The <em>HSE National Service Plan 2018</em> “clearly recognises the challenges posed in managing increased demand for systemic anti-cancer therapy as the number of cancer patients grows, and clearly spells out the need to improve aseptic compounding units in Ireland to improve efficiency”, according to the Society spokesperson.

The Society plans on raising these issues with the HSE and the National Cancer Control Programme in the coming months.

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read